Clinical Trial Search

Primary: Objective Response Rate (CR + PR by RECIST) Paclitaxel, Pemetrexed, and Bevacizumab in Patients With Advanced Non-Small Lung Cancer Who Have Received no Prior Treatment…

Primary: Dyspnea Intensity Measured by the 10-point Borg Scale During Cycle Exercise — 2.6; 2.0 units on a scale

Primary: Safety — 13 participants

Primary: Event Rate of the Composite of Adjudicated Venous Thromboembolism (VTE) Events and All-Cause Death With Onset During the Intended Treatment Period - Primary Subjects…

Primary: Number of Participants Who Demonstrated Acute Adverse Events Following Infusion — 0; 0 participants

Primary: Change From Baseline in Gingival Inflammation on a 4 Point Scale Using the Modified Gingival Index (MGI) at Day 14 — 0.10; 0.10; 0.10; 0.01 units on a scale

Primary: Number of Participants Who Incurred at Least One Treatment Emergent Event — 33; 10 participants

Primary: Mean IOP at Week 6 — 20.2; 18.7; 19.9; 19.3 mmHg

Primary: Incidence of Biopsy Confirmed Acute Rejection at 12 Months. — 5 participants

Primary: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment — -0.40; -0.39 percentage of glycosylated haemoglobin

Primary: Percentage of Participants Achieving an Improvement of at Least 0.22 Units in Health Assessment Questionnaire (HAQ) at Week 24 — 57.9 Percentage

Primary: Success Rate of Lens Centration After 7 ± 2 Days of Wear — 100.0; 86.7 percentage of subjects

Primary: Progression-free Survival — 1.8 Months

Primary: Change in Nocturnal Systolic Blood Pressure Level — -12.6; -17.5 mmHg

Primary: Percentage of Participants With at Least One Hemoglobin Cycling — 31.84 percentage of participants